Subtractive proteomics-guided vaccine targets identification and designing of multi-epitopes vaccine for immune response instigation against Burkholderia pseudomallei
In this study, a methodical workflow using subtractive proteomics, vaccine designing, molecular simulation, and agent-based modeling approaches were used to annotate the whole proteome of Burkholderia pseudomallei (strain K96243) for vaccine designing. Among the total 5717 proteins in the whole proteome, 505 were observed to be essential for the pathogen's survival and pathogenesis predicted by the Database of Essential Genes. Among these, 23 vaccine targets were identified, of which fimbrial assembly chaperone (Q63UH5), Outer membrane protein (Q63UH1), and Hemolysin-like protein (Q63UE4) were selected for the subsequent a...
Source: International Journal of Biological Macromolecules - May 6, 2024 Category: Biochemistry Authors: Fahad M Alshabrmi Eid A Alatawi Source Type: research
The influence of near-infrared therapy on arteriovenous fistula patency in haemodialysis patients: A multicentre, randomised, controlled clinical trial
This study will examine the effects of NIR therapy on AVF.METHODS: A randomised, controlled, open-label, multicentre trial will compare the effect of NIR on AVF patency after 1 year of therapy with that of a control group of patients with existing AVF. One group of patients received NIR treatment above their AVFs, whereas the control group received regular care. The primary outcome is the primary fistula patency rate within 12 months. In addition, acute changes in inflammatory, vasodilatory and haemodynamic parameters after a single treatment in the first 40 participants will be examined. This study was registered in the C...
Source: The Journal of Vascular Access - May 6, 2024 Category: Surgery Authors: Feng Chunyan Jiang Zhenbin Jin Weiyi Men Haiyan Zhu Jinrong Wang Yue Wang Song Su Chunyan Source Type: research
The role of chemoradiotherapy and immunotherapy in stage III NSCLC
Pathol Oncol Res. 2024 Apr 19;30:1611716. doi: 10.3389/pore.2024.1611716. eCollection 2024.ABSTRACTLocally advanced non-small lung cancer encompasses a diverse range of tumors. In the last few years, the treatment of stage III unresectable non-small lung cancer has evolved significantly. The PACIFIC trial opened a new therapeutic era in the treatment of locally advanced NSCLC, establishing durvalumab consolidation therapy as the new standard of care worldwide. A careful evaluation of this type of lung cancer and a discussion of the management of these patients within a multidisciplinary team represents a crucial step in de...
Source: Pathology Oncology Research - May 6, 2024 Category: Pathology Authors: Zsuzsanna Orosz Árpád Kovács Source Type: research
Accuracy of energy and nutrient intake estimation versus observed intake using four technology-assisted dietary assessment methods: a randomized crossover feeding study
CONCLUSIONS: Under controlled conditions, Intake24, ASA24, and mFR-TA estimated average energy and nutrient intakes with reasonable validity, but intake distributions were estimated accurately by Intake24 only (energy and protein). This study may inform considerations regarding instruments of choice in future population surveillance.TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry Number ACTRN12621000209897; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=381165&isReview=true.PMID:38710447 | DOI:10.1016/j.ajcnut.2024.04.030 (Source: Am J Clin Nutr)
Source: Am J Clin Nutr - May 6, 2024 Category: Nutrition Authors: Clare Whitton Clare E Collins Barbara A Mullan Megan E Rollo Satvinder S Dhaliwal Richard Norman Carol J Boushey Edward J Delp Fengqing Zhu Tracy A McCaffrey Sharon I Kirkpatrick Christina M Pollard Janelle D Healy Amira Hassan Shivangi Garg Paul Atyeo Sy Source Type: research
Accuracy of energy and nutrient intake estimation versus observed intake using four technology-assisted dietary assessment methods: a randomized crossover feeding study
CONCLUSIONS: Under controlled conditions, Intake24, ASA24, and mFR-TA estimated average energy and nutrient intakes with reasonable validity, but intake distributions were estimated accurately by Intake24 only (energy and protein). This study may inform considerations regarding instruments of choice in future population surveillance.TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry Number ACTRN12621000209897; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=381165&isReview=true.PMID:38710447 | DOI:10.1016/j.ajcnut.2024.04.030 (Source: The American Journal of Clinical Nutrition)
Source: The American Journal of Clinical Nutrition - May 6, 2024 Category: Nutrition Authors: Clare Whitton Clare E Collins Barbara A Mullan Megan E Rollo Satvinder S Dhaliwal Richard Norman Carol J Boushey Edward J Delp Fengqing Zhu Tracy A McCaffrey Sharon I Kirkpatrick Christina M Pollard Janelle D Healy Amira Hassan Shivangi Garg Paul Atyeo Sy Source Type: research
Advancing cell-based therapy in sepsis: An anesthesia outlook
Chin Med J (Engl). 2024 May 6. doi: 10.1097/CM9.0000000000003097. Online ahead of print.ABSTRACTSepsis poses a health challenge globally owing to markedly high rates of morbidity and mortality. Despite employing bundle therapy over two decades, approaches including transient organ supportive therapy and clinical trials focusing on signaling pathways have failed in effectively reversing multiple organ failure in patients with sepsis. Prompt and appropriate perioperative management for surgical patients with concurrent sepsis is urgent. Consequently, innovative therapies focused on remedying organ injuries are necessitated. ...
Source: Chinese Medical Journal - May 6, 2024 Category: General Medicine Authors: Hui Ye Xiaoyu Zou Xiangming Fang Source Type: research
A Systematic Review of Herbal Interventions for the Management of Cardiovascular Diseases
CONCLUSION: This comprehensive review highlights the potential of herbal interventions as valuable adjuncts or alternatives for managing cardiovascular diseases. Herbal remedies offer diverse mechanisms of action, targeting key CVD risk factors and pathways. While promising, their clinical utility warrants further investigation through well-designed trials to establish their safety and efficacy, paving the way for integrated approaches to cardiovascular disease management. Healthcare providers and patients should engage in informed discussions about the use of herbal interventions alongside conventional therapies in the co...
Source: Current Cardiology Reviews - May 6, 2024 Category: Cardiology Authors: Ankita Wal Neha Verma Senthil Kumar Balakrishnan Vinod Gahlot Sumeet Dwivedi Pankaj Kumar Sahu Mohammad Tabish Pranay Wal Source Type: research
Transforming the Discovery of Targeted Protein Degraders: The Translational Power of Predictive PK/PD Modeling
Clin Pharmacol Ther. 2024 May 6. doi: 10.1002/cpt.3273. Online ahead of print.ABSTRACTTargeted protein degraders (TPDs), an emerging therapeutic modality, are attracting considerable interest with the promise to address disease-related proteins that are not druggable with conventional small molecule inhibitors. Despite their novel mechanism of action, the PK/PD relationship of degraders is still approached with a mindset deeply rooted in inhibitor drugs. Here, we establish how predictive mechanistic modeling specifically tailored to TPDs can significantly enhance the value of the available information during lead generatio...
Source: Clinical Pharmacology and Therapeutics - May 6, 2024 Category: Drugs & Pharmacology Authors: Robin Thomas Ulrich Haid Andreas Reichel Source Type: research
Combination immunotherapy with vaccine and oncolytic HSV virotherapy is time dependent
CONCLUSIONS: These findings substantiate the criticality of combination immunotherapy timing and provide preclinical support for combining SNAPvax with oHSV as a promising treatment approach for both pediatric and adult tumors.PMID:38710101 | DOI:10.1158/1535-7163.MCT-23-0873 (Source: Herpes)
Source: Herpes - May 6, 2024 Category: Infectious Diseases Authors: Stacie K Totsch Andrew S Ishizuka Kyung-Don Kang Sam E Gary Abbey Rocco Aaron E Fan Li Zhou Pablo A Valdes SeungHo Lee Jason Li Luca Peruzzotti-Jametti Sarah Blitz Christopher M Garliss James M Johnston James M Markert Geoffrey M Lynn Joshua D Bernstock G Source Type: research
Antibody Drug Conjugate Sacituzumab Govitecan Enables A Sequential TOP1/PARP Inhibitor Cancer Therapy Strategy in Breast Cancer Patients
CONCLUSIONS: While SG dosed concurrently with talazoparib is not tolerated clinically due to an insufficient therapeutic window, sequential dosing of SG then talazoparib proved a viable strategy. These findings support further clinical development of the combination and suggest that ADC-based therapy may facilitate novel, mechanism-based dosing strategies.PMID:38709212 | DOI:10.1158/1078-0432.CCR-24-0428 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - May 6, 2024 Category: Cancer & Oncology Authors: Aditya Bardia Sheng Sun Nayana Thimmiah James T Coates Bogang Wu Rachel O Abelman Laura Spring Beverly Moy Phoebe Ryan Mark N Melkonyan Ann Partridge Dejan Juric Jeffrey Peppercorn Heather Parsons Seth A Wander Victoria Attaya Brenda Lormil Maria Shellock Source Type: research
Antibody Drug Conjugate Sacituzumab Govitecan Enables A Sequential TOP1/PARP Inhibitor Cancer Therapy Strategy in Breast Cancer Patients
CONCLUSIONS: While SG dosed concurrently with talazoparib is not tolerated clinically due to an insufficient therapeutic window, sequential dosing of SG then talazoparib proved a viable strategy. These findings support further clinical development of the combination and suggest that ADC-based therapy may facilitate novel, mechanism-based dosing strategies.PMID:38709212 | DOI:10.1158/1078-0432.CCR-24-0428 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 6, 2024 Category: Cancer & Oncology Authors: Aditya Bardia Sheng Sun Nayana Thimmiah James T Coates Bogang Wu Rachel O Abelman Laura Spring Beverly Moy Phoebe Ryan Mark N Melkonyan Ann Partridge Dejan Juric Jeffrey Peppercorn Heather Parsons Seth A Wander Victoria Attaya Brenda Lormil Maria Shellock Source Type: research
A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241249690. doi: 10.1177/15330338241249690.ABSTRACTBACKGROUND: Cadonilimab (AK104) is a bispecific IgG-single-chain Fv fragment (ScFv) antibody that binds to PD-1 and CTLA-4. Cadonilimab has shown encouraging anti-tumour activity and a favourable safety profile in several tumour types. In second-line treatment, there is no defined standard of care for patients with extensive-stage small-cell lung cancer (ES-SCLC). Cadonilimab is expected to show substantial clinical efficacy.OBJECTIVE: To assess the antitumor activity and safety of cadonilimab monotherapy or combination with...
Source: Technology in Cancer Research and Treatment - May 6, 2024 Category: Cancer & Oncology Authors: Can Chen Minjun Chen Yuju Bai Yajun Li Jie Peng Biao Yao Jiangping Feng Jian-Guo Zhou Hu Ma Source Type: research
Antibody Drug Conjugate Sacituzumab Govitecan Enables A Sequential TOP1/PARP Inhibitor Cancer Therapy Strategy in Breast Cancer Patients
CONCLUSIONS: While SG dosed concurrently with talazoparib is not tolerated clinically due to an insufficient therapeutic window, sequential dosing of SG then talazoparib proved a viable strategy. These findings support further clinical development of the combination and suggest that ADC-based therapy may facilitate novel, mechanism-based dosing strategies.PMID:38709212 | DOI:10.1158/1078-0432.CCR-24-0428 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - May 6, 2024 Category: Cancer & Oncology Authors: Aditya Bardia Sheng Sun Nayana Thimmiah James T Coates Bogang Wu Rachel O Abelman Laura Spring Beverly Moy Phoebe Ryan Mark N Melkonyan Ann Partridge Dejan Juric Jeffrey Peppercorn Heather Parsons Seth A Wander Victoria Attaya Brenda Lormil Maria Shellock Source Type: research
Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis
CONCLUSIONS: Our study demonstrated BRAFi/MEKi have a decent activity for BRAFV600E ATC patients, especially in the neoadjuvant setting, with a tolerable safety profile. However, further clinical trials are warranted to investigate these findings.PMID:38709445 | DOI:10.1007/s12020-024-03845-w (Source: Cancer Control)
Source: Cancer Control - May 6, 2024 Category: Cancer & Oncology Authors: Jonathan N Priantti Natasha Maranh ão Vieira Rodrigues Francisco Cezar Aquino de Moraes Allyson Guimar ães da Costa Deborah Laredo Jezini Maria Izabel Ovellar Heckmann Source Type: research
Protocol for the development and validation of a patient reported measure (PRM) of treatment burden in stroke
CONCLUSIONS: We aim to create a validated PRM of treatment burden after stroke. PETS-stroke is designed for use as an outcome measure in clinical trials of stroke treatments and complex interventions to ascertain if treatments are workable for patients in the context of their everyday lives.PMID:38708032 | PMC:PMC11064975 | DOI:10.12688/healthopenres.13334.2 (Source: Cancer Control)
Source: Cancer Control - May 6, 2024 Category: Cancer & Oncology Authors: Katie I Gallacher Martin Taylor-Rowan David T Eton Hamish McLeod Lisa Kidd Karen Wood Aleema Sardar Terry J Quinn Frances S Mair Source Type: research
